Pfizer’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.6M Buy
2,151,213
+2,076,213
+2,768% +$26.9M 13.77% 4
2026
Q2
$1.04M Hold
75,000
– – 0.61% 13
2026
Q1
$814K Buy
+75,000
New +$1.06M 0.34% 14

Other funds holding AGMB

Pfizer's AGMB Position: Q3 2026 in Review

Pfizer increased its AgomAb Therapeutics NV (AGMB) stake by 2,768% in Q3 2026, buying an estimated $26.9M and bringing the position to 2,151,213 shares worth $22.6M. The position accounts for 13.77% of the portfolio, ranked #4.

Pfizer first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Pfizer held 2,151,213 shares of AgomAb Therapeutics NV worth $22.6M as of Q3 2026.
  • Pfizer bought 2,076,213 AgomAb Therapeutics NV shares in Q3 2026, an estimated $26.9M.
  • AgomAb Therapeutics NV made up 13.77% of Pfizer's portfolio in Q3 2026, its #4 holding.
  • Pfizer first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Pfizer's 13F filing for Q3 2026, filed 12 Nov 2026.